A Nationwide, Multi-institutional Retrospective Study of Efficacy and Safety of Eribulin in Korean Breast Cancer Patients

简要总结

主要结局

次要结局

• Tumor response rate (TRR)(From the start date of therapy with eribulin to the date of death from any cause or last follow-up (1 day to up to approximately 2 years))
• PFS in eribulin-treated breast cancer participants according to line of treatment for advanced disease and tumor subtype (receptor status and molecular subtype)(From the start date of therapy with eribulin to the date of disease progression or death from any cause (1 day to up to approximately 2 years))
• TRR in eribulin-treated breast cancer participants according to line of treatment for advanced disease and tumor subtype (receptor status and molecular subtype)(From the start date of therapy with eribulin to the date of death from any cause or last follow-up (1 day to up to approximately 2 years))
• Progression-Free Survival (PFS)(From the start date of therapy with eribulin to the date of disease progression or death from any cause (1 day to up to approximately 2 years))
• Number of participants with any treatment-emergent adverse event (TEAE)(6 months)
• Overall Survival (OS)(From the start date of therapy with eribulin to the date of death from any cause or last follow-up (1 day to up to approximately 2 years))
• Time to treatment failure (TTF)(From the first treatment with eribulin to discontinuation of treatment for any reason (1 day to up to approximately 2 years))
• OS in eribulin-treated breast cancer participants according to line of treatment for advanced disease and tumor subtype (receptor status and molecular subtype)(From the start date of therapy with eribulin to the date of death from any cause or last follow-up (1 day to up to approximately 2 years))
• PFS rate in eribulin-treated breast cancer participants comparing early (≤ third line) to late (≥ fourth line) use(From the start date of therapy with eribulin to the date of disease progression or death from any cause (1 day to up to approximately 2 years))
• OS in eribulin-treated breast cancer participants comparing early (≤ third line) to late (≥ fourth line) use(From the start date of therapy with eribulin to the date of death from any cause or last follow-up (1 day to up to approximately 2 years))
• TTF in eribulin-treated breast cancer participants comparing early (≤ third line) to late (≥ fourth line) use(From the first treatment with eribulin to discontinuation of treatment for any reason (1 day to up to approximately 2 years))
• TRR in eribulin-treated breast cancer participants comparing early (≤third line) to late (≥ fourth line) use(From the start date of therapy with eribulin to the date of death from any cause or last follow-up (1 day to up to approximately 2 years))
• Number of participants with the indicated action to TEAEs(6 months)
• Number of participants with TEAEs resulting in discontinuation of eribulin(6 months)
• Number of participants using supportive drugs to treat AEs(6 months)
• Median number of eribulin cycles(6 months)
• Number of participants experiencing a dose reduction(6 months)
• TTF in eribulin-treated breast cancer participants according to line of treatment for advanced disease and tumor subtype (receptor status and molecular subtype)(From the first treatment with eribulin to discontinuation of treatment for any reason (1 day to up to approximately 2 years))
• Mean duration of treatment(6 months)
• Mean duration of response(6 months)
• Mean dose intensity(6 months)
• Number of participants with the indicated reason for treatment discontinuation(6 months)